Cardiovascular smooth muscle cells (SMCs) exist as resting or activated cells. Resting SMCs produce contractile proteins and are nearly transcriptionally inactive; activated SMCs are transcriptionally active and are involved in pathological processes such as atherosclerosis. Soluble guanylate cyclase, protein kinase G, and protein kinase A are present in SMCs, but their levels can be decreased in activated cells. Phosphodiesterase 3 (PDE3) activity is abundant in cardiovascular tissues; both PDE3A and PDE3B are involved in cyclic adenosine monophosphate (cAMP) hydrolysis in these tissues. Cyclic-AMP-hydrolyzing PDE activities are altered during the phenotypic transition of SMCs from the resting to the activated phenotype. Similar changes have been observed in cyclic guanosine monophosphate cGMP-hydrolyzing PDEs, although the impact of these alterations on PDE5 inhibitor-mediated effects requires further study. This report presents the changes in PDE expression that accompany phenotypic modulation of SMCs and discusses the potential impact of these events on PDE5-mediated cell functions.
Introduction
In addition to physiologically based differences in the expression of individual phosphodiesterases (PDEs) in the cells of cardiovascular tissues, the overall cardiovascular health status of patient populations also may impact significantly on both the types and levels of individual PDEs in these tissues. At present, it is unclear if these differences affect pharmacologic agents aimed at PDEs or other enzymes involved in regulating cyclic nucleotide levels in these cells.
This article reviews the current state of knowledge concerning (a) expression of PDEs in cells of the cardiovascular system, (b) changes in PDE expression under certain pathophysiological situations, and (c) the potential implications of altered PDE expression on the effects of PDE5 inhibitors. More specifically, the regulated expression of PDEs in two distinct phenotypes of smooth muscle cells (SMCs) (quiescent/resting and activated/synthetic) will be described.
Quiescent/resting SMCs, normally present in healthy blood vessels that perfuse most organs, contract and relax in response to pulsatile differences in the blood flow and in response to the pharmacologic and physiologic stimuli. This response controls the diameter of blood vessels and, as such, plays an important role in regulating systemic blood pressure. Quiescent/resting SMCs express the contractile proteins required for the generation of contractile forces but are, for the most part, transcriptionally inactive and display a very low rate of proliferation and of directed migration. In contrast, activated/synthetic SMCs are transcriptionally active and exhibit high levels of proliferation and directed migration. Such cells are typically involved in processes related to initial establishment of cardiovascular structures (vasculogenesis) or in the process of neovascularization often associated with vascularization of newly formed tissues in health or disease (angiogenesis). Indeed, activated/synthetic SMCs are present during the development of the cardiovascular system, accumulate in atherosclerotic plaques, and can proliferate and migrate to repopulate the lumen of diseased arteries after successful balloon angioplasty.
The two cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), participate in the regulated functioning of SMCs of each phenotype. Interestingly, levels of some of the enzymes involved in the synthesis of the cyclic nucleotides in SMCs (eg, soluble guanylyl cyclase) or the effects of the cyclic nucleotides in cells (e.g., protein kinase G (PKG), protein kinase A (PKA)) vary in SMCs of differing phenotypes. Indeed, activated/synthetic SMCs generated by the culturing of quiescent arterial SMCs, or in situ as a result of vascular damage, demonstrate markedly lower levels of several enzymes involved in mediating cGMP effects than are found in quiescent/resting SMCs.
Recent work from several laboratories has begun to elucidate differences in PDE expression in SMCs under various conditions. In this context, variants of the PDE3 and PDE4 families play important roles in the hydrolysis of cAMP in SMCs. While both quiescent/resting and activated/synthetic SMCs each express both PDE3 gene products (PDE3A and PDE3B), 1,2 levels of PDE3-based cAMP hydrolysis, and of PDE3A protein expression, is substantially lower in activated/synthetic SMCs than in quiescent/resting SMCs. 3 In contrast to PDE3, levels of PDE4 activity and of PDE4D expression are similar in quiescent/resting and activated/synthetic SMCs.
One of the most interesting modes of regulating PDE3 involves the binding of cGMP to the catalytic domain of these enzymes, thereby causing competitive inhibition of cAMP hydrolysis by these enzymes. This inhibitory effect of cGMP on cAMP hydrolysis accounts for findings that nitric oxide (NO)-releasing vasodilators increased platelet and SMC cAMP, and that these agents synergistically raised cAMP when used in combination with activators of adenylyl cyclase, such as prostaglandin E 1 or isoproterenol. 4, 5 Phosphodiesterase 1C (PDE1C), a calcium-calmodulin regulated enzyme that hydrolyzes both cAMP and cGMP, is also expressed in human SMCs in a phenotype-dependent manner. Indeed, while PDE1C is not expressed in human quiescent/resting SMCs, expression of PDE1C is markedly induced in activated/synthetic human SMCs. High levels of PDE1C expression were observed in primary cultures of SMCs derived from explants of human newborn and adult aortas, and in SMCs cultured from severe atherosclerotic lesions. 6 PDE 1C represented the major cAMP hydrolytic activity in these SMCs. Since inhibition of PDE1C leads to the suppression of human SMC proliferation, PDE1C expression may serve as a useful marker of human SMCs proliferation, 7 and PDE1C inhibitors may target proliferating SMCs in relevant situations such as atherosclerosis.
In conclusion, enzymes of the PDE1, PDE3 and PDE4 families of PDE enzymes participate in the hydrolysis of cAMP in SMCs, and the species from which these cells are isolated and their phenotypes will alter significantly the contribution of each family to cAMP hydrolysis.
Several PDEs participate in the hydrolysis of cGMP in SMCs. Thus, PDE1A and PDE1B, two calcium-calmodulin-regulated PDE1 family enzymes, and PDE5, a cGMP-specific PDE that represents the target of agents used in the treatment of erectile dysfunction (sildenafil, vardenafil and tadalafil), all hydrolyze SMC cGMP. PDE1A and PDE1B are differentially expressed in SMCs of differing phenotypes. The species from which the SMCs are isolated also impact the relative amounts of each PDE1 isoform.
In humans, quiescent/resting SMCs express both PDE1A and PDE1B, while activated/synthetic SMCs express only PDE1A. 6 At present, most data are consistent with levels of PDE5 expression being unaltered between quiescent and activated SMCs. However, given the potential importance of changes in PDE5 expression during phenotypic modulations, and the impact of such differences on PDE5 inhibitor-mediated regulation of SMC function, a thorough and detailed analysis of this issue in human SMCs is needed.
In addition to the phenotype-based difference in PDE activity and expression in SMCs, the subcellular expression pattern of these enzymes and their regulated expression by various signaling systems also differ. For example, while PDE3A and PDE3B are each expressed in SMCs, PDE3A alone is found in cytosolic fractions, while both the PDE3A and PDE3B are expressed in particulate fractions of these cells. Although phosphorylation by PKA activates both the PDE3 variants, only PDE3B levels increase following prolonged elevations in cellular cAMP. 2 Similarly, PDE4D activity and expression increase subsequent to elevated cAMP levels in both quiescent/resting and activated/synthetic SMCs, although the different PDE4D variants involved are phenotype dependent. Thus, although quiescent/resting SMCs increase PDE4 activity through the PKAdependent phosphorylation and increase expression of the endogenously expressed PDE4D variant (PDE4D3), activated/synthetic SMCs respond by activating PDE4D3 and by inducing the expression of two PDE4D variants not expressed in SMCs prior to such treatments (PDE4D1 and PDE4D2). 8 Chronic in vivo exposure to the NO-releasing vasodilator, nitroglycerin, induces expression of Ca 2 þ /calmodulin-stimulated PDE1A1, which preferentially degrades cGMP in the rat aorta. Rats made tolerant to nitroglycerin by continuous infusion for 3 days showed an increase in Ca 2 þ / calmodulin-stimulated PDE1A1 and a 2.3-fold increase in PDE1A1 in their aortas. 9 Selective inhibition of PDE1 partially restored the sensitivity of tolerant vessels to subsequent nitroglycerin exposure. This suggests that increased PDE1A1 activity can decrease cGMP levels and that this mechanism may contribute to the reduction of nitroglycerinmediated vasodilation (Figure 1) . PDE2, a cGMP-stimulated PDE that hydrolyzes either cAMP or cGMP, is not expressed in SMCs.
However, this enzyme is expressed in some vascular endothelial cells (VECs), human platelets and cardiac myocytes (cardiomyocytes), cell types essential to cardiovascular control. As these cell types express PDE2, in addition to other PDEs: (PDE1, PDE3, PDE4 and PDE5 in VECs), (PDE3 and PDE5 in platelets), and (PDE3 and PDE4 in cardiomyocytes), their responses to cGMP-elevating agents, such as NO releasing vasodilators, or the atrial natriuretic peptide (ANP), depend on the relative levels of hydrolysis catalyzed by these enzymes in these cell types. This process has been well studied in blood platelets. Thus, in the presence of an activator of adenylyl cyclase, low concentrations of NO-releasing vasodilators (e.g., nitroprusside, molsidomine) cause a synergistic increase in cAMP due to inhibition of cAMP hydrolysis by cGMP acting at PDE3. 4, 10 However, at higher concentrations of the NO-releasing vasodilators, the PDE3-mediated effect becomes saturated and a cGMP-stimulated hydrolysis of cAMP and cGMP by PDE2 predominates. Indeed, in some circumstances, activation of PDE2 abolished the cAMP-increasing effects of PDE3 inhibitors in cells expressing both PDE2 and PDE3. 10 Similarly, in cardiac fibroblasts, NO production decreased cAMP accumulation largely by the cGMPmediated activation of PDE2. 11 Because VECs express both PDE2 and PDE3 and release NO, and quiescent/resting SMCs depend in large part on PDE3 and PDE4 for cAMP hydrolysis, dynamic regulation of systemic blood pressure may depend on tight regulation of VEC and SMC cAMP through coordinated regulation of such activities in these cells. Indeed, in healthy blood vessels with intact endothelial cell layers, VEC-generated NO regulates vascular tone by regulating SMC cGMP levels. Since, in this context, NO-mediated cGMP might be expected to inhibit constitutively a significant portion of PDE3 activity, one could hypothesize that PDE4 inhibitors might produce a more marked effect on blood pressure than might be expected based on their relatively poor relaxant effects in in vitro experiments with endothelium denuded blood vessel strips (Figure 2) . Indeed, evidence consistent with such a mechanism has been reported previously. 12 Since PDE5 inhibitors would be expected to increase cGMP in many cell types, including SMCs, VECs and platelets, in which levels of both cAMP-and cGMP-hydrolyzing PDE activities play crucial roles in regulating cell functions, 'cross-talk' between PDEs in these cells will likely have marked effects on their activity in tissues. A detailed analysis of these effects will undoubtedly be possible with the highly selective PDE5 inhibitors now available.
The overall cardiovascular status of a patient significantly impacts the levels of the individual PDEs expressed in the cells of tissues of this system, and these differences likely will permit 'cross-talk' between cAMP and cGMP signaling systems, unanticipated from experiments conducted with 'healthy' cardiovascular tissues.
Important questions include:
(1) Can the dynamics of short-form spliced variants significantly alter the specificity of a PDE inhibitor?
Several factors impact this question. First, since PDE-family specific inhibitors act by interfering with active site binding of substrates, it is unlikely that these agents will discriminate between long and short forms of PDEs to an extent sufficient to allow splice-form-based drug selectivity. However, since synthetic/activated SMCs respond to prolonged challenges with cAMP-elevating agents by inducing short forms of PDE4D, while quiescent/resting SMCs do not, and these variants can be anchored at different intracellular sites, effects of inhibitors PDE5 inhibitor cardiovascular effects DH Maurice
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may not be predicted solely on the 'total' PDE catalytic activity of individual cell types.
(2) In cells with PDE2, PDE3 and PDE5, will a PDE5 inhibitor alter the balance between cGMP and cAMP levels?
In blood platelets, the cell type in which this issue has been most carefully studied, the answer is most certainly yes. Indeed, results from these studies would predict that PDE5 inhibitors would influence the activities of PDE2 and PDE3 and, in certain cases, alter the relative importance of these enzymes in cells. Unless it can be shown that selective activation of adenylyl cyclase can be triggered in response to erectogenic stimuli, it is unlikely that sufficient selectivity could be achieved to allow activators of adenylyl cyclase to be used in ED. Selective vasodilation of the pulmonary vasculature with PDE5 inhibitors has been reported. Given the limited number of options available to physicians for the control of pulmonary hypertension, the relative role played by PDE5-mediated hydrolysis of cGMP inhibition, as opposed to activation of soluble guanylyl cyclase, in the control of pulmonary vasodilation is warranted. An extensive literature exists describing reduced levels of several cGMP-regulated enzymes, including soluble guanylyl cyclase, in SMC rendered synthetic/activated by culturing. Some of these enzymes are also less abundant in in vivo situations in which synthetic/activated SMCs are abundant. Although intuitively one would predict that reduced levels of soluble guanylyl cyclase might influence the impact of PDE5 inhibition in cells, a tight coupling between synthesis and hydrolysis of cGMP in most cells might influence this dynamic to attenuate any anticipated reduced effects of PDE5 inhibitors.
All these questions form fertile ground for further studies on the dynamics of PDE expression and cyclic nucleotide-mediated regulation of cardiovascular function.
